Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Non-Small Cell Lung Cancer
Title   A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High PD-L1 Expression (CYPRESS 1)
Summary   The purpose of this research study is to measure how well and how safe AM0010 is in combination with pembrolizumab in treating subjects with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have high PD-L1 expression.
Description   Patients will randomly be placed into one of two groups. Both groups will receive pembrolizumab once every three weeks, but only one group will receive the study drug AM0010. This group will self-administer this injection daily.
IRB Number   18006
Inclusion/Notes   To be eligible for this study patients must meet several criteria, including but not limited to the following: confirmed Stage IV/metastatic or recurrent wild type non-small cell lung cancer (NSCLC), have received no previous therapy for the advanced stage of the disease, patients with tumor tissue high expression of PD-L1 >50%
Status   Open
Start Date   12/26/2017
Principal Name   Jeffery Schneider, MD
Contact Name   Jena Trebendis, RN
Email   Jena.Trebendis@nyulangone.org
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-1811
Alternate Phone   516-663-3115